Arcturus Therapeutics Holdings Inc ARCT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 07/01/22 EDT
16.16UNCH (UNCH)
Volume
22,201
Close
16.16quote price arrow up+0.42 (+2.67%)
Volume
661,250
52 week range
11.70 - 65.00
Loading...
  • Open15.70
  • Day High16.56
  • Day Low15.23
  • Prev Close15.74
  • 52 Week High65.00
  • 52 Week High Date08/10/21
  • 52 Week Low11.70
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap426.95M
  • Shares Out26.42M
  • 10 Day Average Volume1.01M
  • Dividend-
  • Dividend Yield-
  • Beta2.79
  • YTD % Change-56.34

KEY STATS

  • Open15.70
  • Day High16.56
  • Day Low15.23
  • Prev Close15.74
  • 52 Week High65.00
  • 52 Week High Date08/10/21
  • 52 Week Low11.70
  • 52 Week Low Date06/16/22
  • Market Cap426.95M
  • Shares Out26.42M
  • 10 Day Average Volume1.01M
  • Dividend-
  • Dividend Yield-
  • Beta2.79
  • YTD % Change-56.34

RATIOS/PROFITABILITY

  • EPS (TTM)-7.53
  • P/E (TTM)-2.15
  • Fwd P/E (NTM)-3.33
  • EBITDA (TTM)-194.431M
  • ROE (TTM)-73.88%
  • Revenue (TTM)15.48M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,282.61%
  • Debt To Equity (MRQ)34.37%

EVENTS

  • Earnings Date08/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arcturus Therapeutics Holdings Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Arcturus Therapeutics Holdings Inc. is a late-stage global clinical messenger ribonucleic acid (mRNA) medicines company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology...
Peter Farrell Ph.D.
Independent Chairman of the Board
Joseph Payne
President, Chief Executive Officer, Director
Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Andrew Sassine
Chief Financial Officer, Director
Address
10628 Science Center Dr Ste 250
San Diego, CA
92121-1132
United States